For medical treatment to reduce cholesterol levels by most international cardiology and nephrology associations recommended prescriptions of statin as monotherapy or combination with other drugs. The tоpic of this article is devoted to the comparative characteristic of this group of drugs for use in patients with chronic kidney disease associated with dyslipidemia. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of using rosuvastatin, a drug from the group of the last generation of statins.